NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson's Zytiga as a treatment for men with newly diagnosed advanced prostate cancer, drawing criticism fr
Johnson & Johnson (J&J) has kicked off results season with a downbeat forecast for the year as competition to some of its top products starts to have an impact on revenues.
Johnson & Johnson has lost another round in its patent defence for prostate cancer blockbuster Zytiga, raising the possibility that generics could launch in the coming days.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
